Weight-loss drug may increase risk of cancer: FDA
A weight-loss drug may be associated with an increased risk of cancer, according to the Food and Drug Administration.
The agency says a clinical trial of Belviq showed a "possible increased risk of cancer." The alert does not say what types of cancer were diagnosed.
However, the FDA says it is still reviewing the trial's results.
Belviq was approved for weight loss in 2012.